Clinical case 1-2026: 64-year-old man with progressive muscle weakness and dyspnea

Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev. 2008;21(3):473-94. doi:10.1128/CMR.00001-08

Uslu S. Myositis due to COVID-19. Postgrad Med J. 2021;97(1148):399. doi:10.1136/postgradmedj-2021-139725

Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734-47. doi:10.1056/NEJMra1402225

Sun KY, Fan Y, Wang YX, Zhong YJ, Wang GF. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020. Semin Arthritis Rheum. 2021;51(1):175-91. doi:10.1016/j.semarthrit.2020.11.009

Hu Q, Huang KC, Goh CH, Tsuchiya Y, Liu Y, Qiu H. Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan. Sci Rep. 2023;13(1):17172. doi:10.1038/s41598-023-44092-9

Leclair V, Notarnicola A, Vencovsky J, Lundberg IE. Polymyositis: does it really exist as a distinct clinical subset? Curr Opin Rheumatol. 2021;33(6):537-43. doi:10.1097/BOR.0000000000000837

Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689-701. doi:10.1038/s41584-020-00515-9

Tang Q, Xie X, He J, Li F, Chen J, Mao N. Clinical characteristics of idiopathic inflammatory myopathies related to anti-SRP: a single center experience. Sci Rep. 2024;14(1):25788. doi:10.1038/s41598-024-74940-1

Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257-72. doi:10.1038/s41584-019-0186-x

Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med. 2019;8(11):2013. doi:10.3390/jcm8112013

Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol. 2017;44(7):1051-7. doi:10.3899/jrheum.161480

Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;37(1):100-9. doi:10.1590/S1806-37132011000100015

Plastiras SC, Soliotis FC, Vlachoyiannopoulos P, Tzelepis GE. Interstitial lung disease in a patient with antisynthetase syndrome and no myositis. Clin Rheumatol. 2007;26(1):108-11. doi:10.1007/s10067-005-0111-3

Liu Y, Liu X, Xie M, Chen Z, He J, Wang Z, et al. Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review. Respir Med. 2020;165:105920. doi:10.1016/j.rmed.2020.105920

Sasano H, Hagiwara E, Kitamura H, Enomoto Y, Matsuo N, Baba T, et al. Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy. BMC Pulm Med. 2016;16(1):168. doi:10.1186/s12890-016-0325-y

Savige JA, Paspaliaris B, Silvestrini R, Davies D, Nikoloutsopoulos T, Sturgess A, et al. A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. J Clin Pathol. 1998;51(8):568-75. doi:10.1136/jcp.51.8.568

Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol. 2020;34(4):101503. doi:10.1016/j.berh.2020.101503

Leclair V, Lundberg IE. New myositis classification criteria: what we have learned since Bohan and Peter. Curr Rheumatol Rep. 2018;20(4):18. doi:10.1007/s11926-018-0726-4

Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976-87. doi:10.1183/13993003.00150-2015

Decker P, Sobanski V, Moulinet T, Launay D, Hachulla E, Valentin V, et al. Interstitial pneumonia with autoimmune features: evaluation of connective tissue disease incidence during follow-up. Eur J Intern Med. 2022;97:62-8. doi:10.1016/j.ejim.2021.12.021

Tang HS, Tang IY, Ho RT, Young JK, Lai BT, Chung JY, et al. Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centred retrospective cohort study. Rheumatology (Oxford). 2025;64(1):212-20. doi:10.1093/rheumatology/kead671

Gasparotto M, Gatto M, Saccon F, Ghirardello A, Iaccarino L, Doria A. Pulmonary involvement in antisynthetase syndrome. Curr Opin Rheumatol. 2019;31(6):603-10. doi:10.1097/BOR.0000000000000663

Alexander J, Packham S, Warwick G, Mohan Das L. Spontaneous pneumomediastinum: an unusual but serious complication of dermatomyositis. BMJ Case Rep. 2014;2014:bcr2014206787. doi:10.1136/bcr-2014-206787

Parodis I, Girard-Guyonvarc'h C, Arnaud L, Distler O, Domján A, Van den Ende CHM, et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. 2024;83(6):720-9. doi:10.1136/ard-2023-224416

Hallowell RW, Paik JJ. Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clin Exp Rheumatol. 2022;40(2):373-83. doi:10.55563/clinexprheumatol/brvl1v

Sehgal S, Patel A, Chatterjee S, Fernandez AP, Farver C, Yadav R, et al. Idiopathic inflammatory myopathies related lung disease in adults. Lancet Respir Med. 2025;13(3):272-88. doi:10.1016/S2213-2600(24)00267-4

Storrer KM, Müller CS, Pessoa MC, Pereira CA. Connective tissue disease-associated interstitial lung disease. J Bras Pneumol. 2024;50(1):e20230132. doi:10.36416/1806-3756/e20230132

Jung J, Kim MJ, Yoo B, Lee CK, Kim YG, Hong S, et al. Clinical impact of pneumomediastinum in patients with myositis-associated interstitial lung disease. PLoS ONE. 2025;20(7):e0328043. doi:10.1371/journal.pone.0328043